Search results
Showing 961 to 975 of 1490 results for patients and public
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC
Awaiting development Reference number: GID-TA11637 Expected publication date: TBC
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
In development Reference number: GID-IPG10441 Expected publication date: 17 December 2026
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
This indicator covers the percentage of patients who reached 75 years old in the preceding 12 months, who have received a shingles vaccine between the ages of 70 and 75 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM201
Evidence-based recommendations on scleral expansion surgery for presbyopia. This involves making small incisions in the eye and inserting bands to stretch part of the sclera.
View recommendations for HTG43Show all sections
Sections for HTG43
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
In development Reference number: GID-IPG10437 Expected publication date: TBC
In development Reference number: GID-IPG10405 Expected publication date: 19 November 2026